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 Approximately 3% of invasive breast cancers can be attributed to a 
mutation in  BRCA1 or  BRCA2 ( 1 ). Women who carry a  BRCA1 
mutation face a lifetime risk of breast cancer of 60% – 80% ( 2 , 3 ), but 
the risk can be reduced substantially by performing surgical 
oophorectomy before menopause ( 4 ). Because the observed reduc-
tion in risk is believed to be due to the withdrawal of ovarian hor-
mones, concern has been raised that administration of exogenous 
hormones in the form of hormone therapy (HT) given to help alle-
viate the climacteric symptoms associated with menopause may 
increase the risk of breast cancer, either in women undergoing sur-
gical oophorectomy or in women following  natural menopause. 
The majority of HT preparations contain estrogen, but not all con-
tain progesterone. In the Women’s Health Initiative randomized 
trial, a statistically signifi cant increase in the risk of breast cancer 
was seen in association with the use of combined therapy (estrogen 
plus progesterone) but not with estrogen alone ( 5 – 8 ). One study has 
been conducted in  BRCA1 mutation carriers; Rebbeck et al. ( 9 ) 
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 ARTICLE 
 Hormone Therapy and the Risk of Breast Cancer in 
 BRCA1 Mutation Carriers 
 Andrea  Eisen ,  Jan  Lubinski ,  Jacek  Gronwald ,  Pal  Moller ,  Henry T.  Lynch ,  Jan  Klijn ,  Charmaine  Kim-Sing , 
 Susan L.  Neuhausen ,  Lucy  Gilbert ,  Parviz  Ghadirian ,  Siranoush  Manoukian ,  Gad  Rennert ,  Eitan  Friedman , 
 Claudine  Isaacs ,  Eliot  Rosen ,  Barry  Rosen ,  Mary  Daly ,  Ping  Sun ,  Steven A.  Narod ,  and  the Hereditary 
Breast Cancer Clinical Study Group 
  Background  Hormone therapy (HT) is commonly given to women to alleviate the climacteric symptoms associated 
with menopause. There is concern that this treatment may increase the risk of breast cancer. The potential 
association of HT and breast cancer risk is of particular interest to women who carry a mutation in  BRCA1 
because they face a high lifetime risk of breast cancer and because many of these women take HT after 
undergoing prophylactic surgical oophorectomy at a young age. 
  Methods  We conducted a matched case – control study of 472 postmenopausal women with a  BRCA1 mutation to 
examine whether or not the use of HT is associated with subsequent risk of breast cancer. Breast cancer 
case patients and control subjects were matched with respect to age, age at menopause, and type of 
menopause (surgical or natural). Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated 
with conditional logistic regression. Statistical tests were two-sided. 
  Results  In this group of  BRCA1 mutation carriers, the adjusted OR for breast cancer associated with ever use of 
HT compared with never use was 0.58 (95% CI = 0.35 to 0.96;  P = .03). In analyses by type of HT, an inverse 
association with breast cancer risk was observed with use of estrogen only (OR = 0.51, 95% CI = 0.27 to 
0.98;  P = .04); the association with use of estrogen plus progesterone was not statistically significant (OR = 
0.66, 95% CI = 0.34 to 1.27;  P = .21). 
  Conclusion  Among postmenopausal women with a  BRCA1 mutation, HT use was not associated with increased risk 
of breast cancer; indeed, in this population, it was associated with a decreased risk. 
  J Natl Cancer Inst 2008;100: 1361 – 1367 
 Affiliations of authors: Sunnybrook Regional Cancer Center, Toronto, 
Ontario, Canada (AE); Hereditary Cancer Center, Pomeranian Medical 
University, Szczecin, Poland (JL, JG); Section of Cancer Genetics, 
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found inverse associations between oophorectomy and breast can-
cer risk among women who did and who did not use HT. However, 
that study ( 9 ) included both pre- and postmenopausal women, and 
the authors did not directly compare the risks of breast cancer in 
postmenopausal women who did and did not take HT. We carried 
out a case – control study of  BRCA1 mutation carriers that was 
restricted to postmenopausal women, and we examined whether or 
not the use of HT following surgical or natural menopause is associ-
ated with the subsequent risk of breast cancer. 
 Subjects and Methods 
 Study Population and Data Collection 
 Eligible study subjects were identified from a cohort of living 
women from one of 55 participating centers in nine countries who 
were participants in ongoing clinical research protocols at the host 
institutions. All study subjects (with the exception of those from the 
University of Utah) received genetic counseling and provided writ-
ten informed consent for genetic testing. In most cases, testing was 
initially offered to women who had been affected with breast or 
ovarian cancer. When a  BRCA1 or  BRCA2 mutation was identified 
in a proband or a relative, genetic testing was offered to other at-
risk women in the family. Mutation detection was performed using 
a range of techniques, but all nucleotide sequences were confirmed 
by direct sequencing of DNA. A woman was eligible for the cohort 
when molecular analysis established that she was a carrier of a 
deleterious mutation in  BRCA1 or  BRCA2 . Most (>95%) of the 
mutations identified in the study subjects were nonsense mutations 
or small deletions, insertions, or frameshifts. The cohort was 
established in 1995 as part of a prospective study designed to evalu-
ate nongenetic modifiers of cancer risk in  BRCA1 and  BRCA2 
mutation carriers, such as HT and oral contraceptives. Data on oral 
contraceptive use and breast cancer and ovarian cancer risk in this 
population have been published previously ( 10 , 11 ). The institu-
tional review boards of the host institutions approved the study. 
 A questionnaire was administered to each woman in the cohort at 
the time of a clinic appointment or at their home at a later date. In 
some centers, questionnaires were mailed to the study subjects. 
Variables of interest included information on demography and eth-
nic group. Information was requested from the study centers on the 
estrogen receptor (ER) status of the tumors of the case patients; 
however, ER status was available for only 44% of the case patients. 
The questionnaire included questions about the women’s medical 
and reproductive histories and selected lifestyle factors, including 
past and current use of HT. The subjects were asked if they had ever 
taken HT, what year they began using HT, what year they stopped 
using HT, the total duration of HT use, and whether they currently 
used HT. Information about the type of HT was also requested. 
 Subjects for the current study were drawn from the 6062 women 
within the cohort with a  BRCA1 mutation. In total, 2415  women 
had reached menopause without a diagnosis of breast cancer. Of 
these, we excluded 349 women because we could not determine 
their menopausal status (eg, hysterectomy without oophorectomy) 
or because data were missing on key variables related to menopause. 
Data were missing on HT for 67 women, and these women were 
also excluded. This group of 67 included 45 women who reported 
having used HT in the past but could not recall the name of the 
drug. A total of 37 women who reported having used HT before 
menopause were also excluded. We excluded 1010 women who had 
been diagnosed with ovarian, fallopian, peritoneal, or omental can-
cer and 15 women who were diagnosed with another form of can-
cer. We excluded 99 women who underwent bilateral preventive 
mastectomy and 17 women who took tamoxifen for prophylaxis. 
After these exclusions, there remained 821 postmenopausal women 
who were eligible for the study, including 304 women with breast 
cancer (potential case patients) and 517 women without breast can-
cer (potential control subjects). The potential case patients had 
been diagnosed with invasive cancer of the breast after reaching 
menopause (ie, in the year before menopause or thereafter). They 
had been diagnosed before the completion of the questionnaire 
(median year of diagnosis 1997; range = 1959 – 2005). The diagnosis 
of breast cancer was confi rmed at the time the case patient under-
went genetic testing at the collaborating center. Control subjects 
had also undergone menopause but did not subsequently develop 
breast cancer. A single control subject was selected for each case 
patient, matched according to year of birth (within 2 years), age at 
menopause (within 2 years), and type of menopause (surgical vs 
natural). A total of 236 matched sets were generated. 
 Statistical Analysis 
 A matched case – control analysis was performed. McNemar test 
was used to test for differences in categorical variables with two 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 Use of hormone therapy (HT) after menopause may increase the 
risk of breast cancer in the general population. The effects of HT 
in women with mutations in the  BRCA1 gene, however, are not 
known. 
 Study design 
 Case – control study of postmenopausal women who carry a  BRCA1 
mutation to compare the risks of breast cancer among those who 
used HT and those who did not. 
 Contribution 
 In this study of  BRCA1 mutation carriers, a decrease in breast can-
cer risk was observed among those who took HT compared with 
those who did not. 
 Implications 
 HT use does not appear to be associated with an increased risk for 
breast cancer among postmenopausal women who carry a  BRCA1 
mutation. Indeed, in this study, it was associated with a decreased 
risk among such women. 
 Limitations 
 The study was relatively small, women who had undergone preven-
tive mastectomy or used tamoxifen were excluded, and the results 
depended on the participants ’ recall of HT use. An average of 
approximately 5.6 years had elapsed between breast cancer diagno-
sis and the completion of the questionnaire, so if  BRCA1 mutation 
carriers who previously took HT have shorter survival after breast 
cancer diagnosis than those who did not take HT, this would have 
skewed the results in the negative direction that was observed. 
 From the Editors 
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 Table 1 .  Characteristics of case patients and control subjects 
 Variables Control subjects (n = 236) Case patients (n = 236)  P * 
 Year of birth, mean 1943 1943  
 Age at interview (range), y 58.2 (32 – 85) 58.2 (34 – 81) .71 
 Year of interview (range) 2001 (1991 – 2006) 2001 (1988 – 2007) .55 
 Age at diagnosis (range), y NA 52.6 (30 – 80)  
 Menopause type, No. (%)  
  Natural 174 (74) 174 (74)  
  Surgical 62 (26) 74 (26)  
 Age at menopause (range), y 47.2 (28 – 58) 46.9 (28 – 57)  
  Natural 48.8 (38 – 58) 48.5 (40 – 57)  
  Surgical 42.6 (28 – 52) 42.3 (28 – 52)  
 Hormone therapy use, No. (%) 68 (29) 47 (20) .02 
  Mean duration, y, users 3.7 4.0 .70 
  Mean duration, y, all 1.1 0.8 .23 
 Oral contraceptive use, ever, No. (%) 102 (43) 95 (41) .70 
 Smoker, ever, No. (%) 107 (48) 112 (49) .85 
Nulliparous, No. (%) 22 (9) 20 (9) .87 
  Mean parity 2.5 2.5 .57 
 Mean no. of first-degree relatives 
 with breast cancer
0.8 0.9 .36 
 Country of residence, No. (%) .50 
  Israel 13 (6) 15 (6)  
  Poland 80 (34) 96 (41)  
  United States 57 (24) 52 (22)  
  Canada 40 (17) 37 (16)  
  Other Europe (Italy, Norway, United 
  Kingdom, Sweden, and The Netherlands)
46 (20) 36 (15)  .65 
 Ethnic group, No. (%) .50 
  Other white 233 (82) 183 (78)  
  Jewish 53 (14) 40 (17)  
  French Canadian 15 (3) 10 (4)  
  Other 2 (1) 3 (1)  
 *  P values (two-sided) were calculated using paired  t test for continuous variables or McNemar test for categorical variables.  P values were not calculated 
for variables used for matching (ie, age at menopause and type of menopause). NA = not applicable. 
categories. If there were more than two categories, then the marginal 
homogeneity test was used. The univariate odds ratios (ORs) and 
95% confidence intervals (CIs) for breast cancer associated with HT 
use were estimated using conditional logistic regression for matched 
sets. We considered HT use only in the years before diagnosis of 
breast cancer in the case patients; that is, a control subject who first 
used HT after the age of diagnosis of her matched case patient was 
considered to be unexposed. We conducted a subanalysis to evaluate 
the relationship of current use (vs past or never use) with the risk of 
breast cancer. We also evaluated the association with duration of use; 
subjects were divided into those who used HT for 3 years or less vs 
more than 3 years (roughly the median duration of use among con-
trol subjects). HT preparations were divided into those containing 
estrogen only or estrogen and progesterone. Only three women took 
progesterone-only HT, and they were excluded from the subgroup 
analysis. A multivariable analysis was carried out to control for the 
potential confounding effects of oral contraceptive use, parity, and 
country of residence. Oral contraceptive use was coded as ever or 
never use, and parity was coded as zero, one, two, or three or more 
births. Data were analyzed separately for women with natural and 
surgical menopause and for both groups combined. All statistical 
tests were two-sided. All analyses were performed using the SAS 
statistical package, version 9.1.3 (SAS Institute, Cary, NC).  P values 
less than .05 were considered as statistically significant. 
 Results 
 We identified a total of 236 matched pairs of  BRCA1 mutation 
carriers. The breast cancer case patients and control subjects 
were similar with respect to date of birth, age at menopause, age 
and year at interview, oral contraceptive use, smoking status, 
and parity ( Table 1 ). Case patients and control subjects were 
matched on both age at menopause and type of menopause; this 
strategy was successful in generating groups of case patients and 
control subjects who were similar in terms of their menopausal 
histories, family histories, and other demographic factors. Most 
(74%) of the case patients and control subjects had undergone 
natural menopause. 
 We examined the relationship between HT use and the risk 
of breast cancer in  BRCA1 mutation carriers ( Tables 1 and  2 ). A 
higher proportion of control subjects than case patients had used 
HT at some time (29% vs 20%), and the difference was statistically 
signifi cant ( P = .02). Among women who ever used HT, the aver-
age duration of HT use was similar for the case patients (4.0 years) 
and the control subjects (3.7 years) ( P = .7). 
 A multivariable analysis was conducted, adjusting for parity, 
oral contraceptive use, and country of origin. Compared with 
those who had never used HT, women who had used HT had a 
lower risk of breast cancer (OR = 0.58%, 95% CI = 0.35 to 0.96; 
 P = .03) ( Table 2 ). The OR estimates were similar in the subgroups 
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of  BRCA1 mutation carriers who had undergone surgical (OR = 
0.48, 95% CI = 0.19 to 1.21) and natural (OR = 0.68, 95% CI = 
0.37 to 1.27) menopause; however, the former category was small 
(n = 62 pairs), and neither association was statistically signifi cant in 
the multivariable analysis ( Table 2 ). 
 We evaluated the association between HT and breast 
cancer risk in subgroups defi ned by duration and timing of use 
and type of HT preparation. The OR did not depend on the 
age at diagnosis or the age at menopause ( Table 3 ). There was 
no apparent modifi cation of the OR with duration of use ( Table 
4 ), and the association was similar for current users and past 
users ( Table 4 ). The association was similar for women who 
used estrogen alone and those who used combined therapy 
( Table 5 ). 
 Information was available regarding ER status for 103 case 
patients (44%). If HT were a risk factor for ER-positive breast 
cancer but not ER-negative breast cancer, then we would expect 
previous HT use to be greater among women with ER-positive 
breast cancers than among women with ER-negative breast can-
cers. This was not the case; HT use was reported for 12% (4 of 33) 
patients with ER-positive tumors and for 23% of patients (16 of 
70) with ER-negative tumors ( P = .29). 
 Discussion 
 These findings suggest that the use of HT is not associated with an 
increase in the risk of breast cancer among women with a  BRCA1 
mutation. We were interested in examining HT use and breast 
cancer risk in  BRCA1 mutation carriers because oophorectomy has 
become a standard of care in North America and Western Europe 
for preventing cancer in women with a  BRCA1 or  BRCA2 mutation. 
Currently, after receiving a positive genetic test result, 68% of 
women in the United States and 54% of women in Canada with a 
 BRCA1 or  BRCA2 mutation undergo oophorectomy ( 12 ). The sur-
gery has been associated with risk reductions of 50% or more for 
breast cancer ( 4 ) and of 80% for ovarian or peritoneal cancer ( 13 ). 
Some women might be reluctant to undergo premenopausal 
oophorectomy because of the effects of surgical menopause and are 
concerned that if HT were taken to alleviate symptoms, then their 
risk of breast cancer might rise. 
 We observed an OR below unity, indicative of an inverse asso-
ciation between HT use and breast cancer risk. The magnitude of 
the association appeared to be as great, or even greater, for women 
after surgical menopause than it was for women after natural meno-
pause. This information should be reassuring to women who wish 
 Table 2 .  Risk of breast cancer with HT use by type of menopause * 
 Type of menopause Control subjects, No. Case patients, No.
OR (95% CI) 
 Unadjusted  P Multivariable  P 
 Surgical (62 pairs)   
  No HT 28 39 1 (referent) 1.0 (referent)  
  HT 34 23 0.43 (0.18 to 0.96) .04 0.48 (0.19 to 1.21) .12 
 Natural (174 pairs)   
  No HT 140 34 1 (referent) 1.0 (referent)  
  HT 150 24 0.67 (0.38 to 1.17) .16 0.68 (0.37 to 1.27)  .22
 All (236 pairs)   
  No HT 168 189 1.0 (referent) 1.0 (referent)  
  HT 68 47 0.57 (0.39 to 0.91) .02 0.58 (0.35 to 0.96) .03
 *  Multivariable ORs were adjusted for parity (0, 1, 2, or  ≥ 3), oral contraceptive use (never vs ever), and country of residence.  P values (two-sided) were calculated 
using conditional logistic regression. HT = hormone therapy; OR = odds ratio; CI = confidence interval. 
 Table 3 .  Risk of breast cancer with HT use by age at menopause and age at diagnosis * 
OR (95% CI)
 Variable Control subjects, No. Case patients, No. Univariate  P Multivariable  P 
 Age at menopause   
  ≤ 45 y   
   No HT 46 57 1 (referent) 1 (referent)  
   HT 32 21 0.52 (0.26 to 1.05) .07 0.50 (0.23 to 1.10) .08 
  >45 y   
   No HT 122 132 1 (referent) 1 (referent)  
   HT 36 26 0.62 (0.33 to 1.15) .13 0.62 (0.32 to 1.21) .16 
 Age at diagnosis   
  ≤ 50 y  
   No HT 52 63 1 (referent) 1 (referent) 
   HT 32 21 0.50 (0.24 to 1.03) .06 0.49 (0.23 to 1.04) .06
  >50 y  
   No HT 116 126 1 (referent) 1 (referent) 
   HT 36 26 0.63 (0.34 to 1.16) .14 0.63 (0.34 to 1.16) .22
 *  Multivariable ORs adjusted for parity (0, 1, 2, or  ≥ 3), oral contraceptive use (never vs ever), and country of residence.  P values (two-sided) were calculated 
using conditional logistic regression. HT = hormone therapy; OR = odds ratio; CI = confidence interval. 
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to undergo preventive oophorectomy before menopause, but it 
needs to be confi rmed in subsequent studies. Premenopausal 
women face a greater residual risk of breast cancer than do women 
who have entered menopause; for them, the net reduction in breast 
cancer risk associated with oophorectomy is substantial ( 4 ). In the 
noncarrier population, the increased breast cancer risk associated 
with HT appears to be stronger for ER-positive cancers than 
ER-negative cancers ( 14 ). If HT were a risk factor for ER-positive 
breast cancer in  BRCA1 mutation carriers as well, we would have 
expected that a greater proportion of women with ER-positive 
breast cancers had used HT than women with ER-negative breast 
cancers. This was not seen, but because we were able to obtain ER 
status for only about one-half of the breast cancer patients, the 
numbers are too small to draw a defi nite conclusion. 
 In this study, neither use of estrogen alone nor use of estrogen 
combined with progesterone was associated with an increase in 
breast cancer risk among  BRCA1 mutation carriers. This observa-
tion is in contrast to the situation in the general (ie, noncarrier) 
population, in which formulations containing both estrogen and 
progesterone have been associated with a substantial increase in 
breast cancer risk. For example, in the Women’s Health Initiative 
randomized trial, a hazard ratio (HR) of 1.3 (95% CI = 1.0 to 1.6) 
was reported for breast cancer in association with use of estrogen 
plus progesterone ( 5 , 6 ), and an HR of 0.8 (95% CI = 0.6 to 1.0) 
was reported for estrogen alone ( 7 , 8 ). In the Million Women 
Study ( 15 ), an HR of 2.0 (95% CI = 1.9 to 2.1) was associated with 
current use of estrogen plus progesterone, and an HR of 1.3 (95% 
CI = 1.2 to 2.4) was associated with current use of estrogen alone. 
 The increase in breast cancer risk in the Million Women Study 
was restricted to current HT users; after treatment stopped, the 
risk dissipated rapidly. A rapid and reversible effect might be seen 
if HT accelerated the growth of existing ER-positive tumors or 
preneoplastic lesions. The majority of  BRCA1 -associated breast 
cancers in our study (68%) were ER negative; if the adverse effect 
of HT were limited to ER-positive cancers, then we would not 
expect to see an acute effect of similar magnitude in mutation car-
riers. It may be also that HT use protects against the early stages 
of cancer development, which results in a decline in the incidence 
of breast cancer later in life. The Women’s Health Initiative ran-
domized trial ( 5 – 8 ) measured the combined effect of past and cur-
rent use of estrogen on breast cancer risk; the OR for estrogen 
alone was borderline protective (OR = 0.77, 95% CI = 0.59 to 
1.01). It has been proposed that the rapid decline in breast cancer 
risk seen in the United States in 2003 is the consequence of a drop 
in HT usage in the preceding years ( 14 ). The decline in incidence 
was most pronounced for ER-positive tumors, favoring the 
hypothesis that the use of HT is associated with a rapid but revers-
ible increase in the risk of ER-positive breast cancers. If HT pro-
motes the growth of existing ER-positive breast cancers but 
protects against the early stages of development of new breast 
cancers (ER positive and ER negative), then we would expect HT 
to protect against breast cancer in  BRCA1 mutation carriers (which 
are mostly ER negative). 
 We saw no association between the duration of HT use and the 
risk of breast cancer among  BRCA1 mutation carriers, and the 
association with past use was similar to that of current use. This 
observation is consistent with the hypothesis that transient expo-
sure to HT is protective; ie, HT might induce the differentiation 
of precursor cancer cells and thereby prevent cancer later in life. It 
is of interest that both tamoxifen and oophorectomy are also effec-
tive in reducing the risk of postmenopausal breast cancer in 
 BRCA1 mutation carriers ( 4 , 16 ). It may be that estrogens and anti-
estrogens modify breast cancer risk at different stages of progres-
sion. For example, estrogen might act early in carcinogenesis, on 
stem cells or preneoplastic lesions, and tamoxifen and oophorec-
tomy might act at a later stage, eg, in small established cancers. 
 Table 4 .  Risk of breast cancer by duration and time of HT use * 
OR (95% CI)
 Variable Control subjects, No. Case patients, No. Univariate  P Multivariable  P 
 Duration of HT, y  
  No HT 168 189 1 (referent) 1 (referent)  
  HT  ≤ 3 41 31 0.61 (0.34 to 1.12) .11 0.63 (0.34 to 1.16) .14 
  HT >3 27 16 0.52 (0.26 to 1.02) .06 0.51 (0.24 to 1.08) .08 
 Time of use  
  Never 168 189 1 (referent) 1 (referent)  
  Current use 51 39 0.64 (0.39 to 1.07) .09 0.63 (0.37 to 1.07) .09 
  Past use 17 8 0.43 (0.14 to 0.94) .04 0.43 (0.16 to 1.17) .10 
 *  Multivariable ORs adjusted for parity (0, 1, 2, or  ≥ 3), oral contraceptive use (never vs ever), and country of residence.  P values (two-sided) were calculated 
using conditional logistic regression. HT = hormone therapy; OR = odds ratio; CI = confidence interval. 
 Table 5 .  Risk of breast cancer by HT formulation * 
 Formulation Control subjects, No. Case patients, No.
OR (95% CI) 
 Unadjusted  P Multivariable  P 
 No HT 168 189 1 (referent) 1 (referent) 
 Estrogen 40 28 0.53 (0.29 to 0.97) .04 0.51 (0.27 to 0.98) .04
 Estrogen + progesterone 28 19 0.56 (0.30 to 1.04) .07 0.66 (0.34 to 1.27) .21
 *  Multivariable odds ratios adjusted for parity (0, 1, 2, or  ≥ 3), oral contraceptive use (never vs ever), and country of residence.  P values (two-sided) were calculated 
using conditional logistic regression. HT = hormone therapy; OR = odds ratio; CI = confidence interval. 
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 Another possible reason for the inverse association we observed 
between HT and breast cancer risk in  BRCA1 mutation carriers 
is that estrogen increases expression of  BRCA1 ( 18 ). In cells that 
have not undergone loss of homozygosity (ie, that retain one nor-
mal  BRCA1 allele), this increase could lead to an increased cel-
lular level of the wild-type protein, and thereby promote genetic 
stability. 
 There is one previous study of HT in  BRCA1 and  BRCA2 
mutation carriers. Rebbeck et al. ( 9 ) examined the association 
bet ween oophorectomy and breast cancer risk in a historical 
co hort study of 462  BRCA1 and  BRCA2 mutation carriers. They 
found that the OR for breast cancer associated with oophorectomy 
was 0.40 (95% CI = 0.18 to 0.92) in the entire study group and 0.37 
(95% CI = 0.14 to 0.96) in the subgroup of women with oophorec-
tomy who used HT. However, in that study, use of HT was not 
evaluated independently of menopause because the sample size was 
small (there were only three women with breast cancer and HT 
exposure in the study by Rebbeck et al., compared with 47 in the 
current study). 
 Other areas of concern with regard to the secondary effects of 
HT in  BRCA1 mutation carriers include possibly elevated risks of 
endometrial and ovarian cancer. In the general population, estro-
gen alone is avoided in women with an intact uterus because of the 
established association between unopposed estrogen and endome-
trial cancer ( 17 ). In a recent study, we reported that the risk of 
endometrial cancer was increased in a cohort of carriers of  BRCA1 
mutations, compared with noncarrier conrol subjects, but the 
increase was statistically signifi cant only in those with past tamox-
ifen use ( 18 ). Of the six women with incident endometrial cancer 
observed in this earlier study, four women had a past history of 
tamoxifen use, but none had previously taken HT. A recent analy-
sis of the Million Women Study ( 19 ) found an increased risk of 
1.2 (95% CI = 1.1 to 1.3) for ovarian cancer in association with 
HT use. However, in a small study of HT in  BRCA1 and  BRCA2 
mutation carriers ( 20 ), we did not see any increase in the risk of 
ovarian cancer in women with a past use of HT (OR = 0.93, 95% 
CI = 0.56 to 1.56). 
 The principal strength of our study is that we restricted our 
observations to postmenopausal women, that is, women who are 
candidates for HT. Case patients and control subjects were closely 
matched for age and age at menopause. 
 Our study also has limitations. One is the relatively small 
sample size. From a database containing more than 6000 
patients, we studied 236 matched pairs of women with and with-
out breast cancer. The average age at interview of the case 
patients and control subjects was 58 years. This subgroup repre-
sents a small proportion of the overall  BRCA1 mutation cohort; 
however, most women in the database could not contribute to 
the study, either because they had not yet reached menopause or 
because they had developed early-onset breast cancer. Women 
who had preventive mastectomy or who used tamoxifen were 
also excluded. 
 There is also the possibility of unmeasured confounders. By 
matching on age and type of menopause, we excluded the potential 
for bias that might arise if the age of menopause or type of meno-
pause were correlated with the likelihood of receiving hormones. 
However, if other (currently unknown) factors correlate with the 
decision to take HT, these factors could potentially lead to a bias 
in the results. 
 Third, the validity of our results depends on the accuracy of the 
subjects ’ recall. The women in the study reported on the type of 
hormone preparation and the duration of use, but these values 
were not confi rmed by review of medical records. Women who 
were unsure of the hormone formulation were excluded. We 
divided exposures by duration of HT but did not classify exposures 
according to the doses of the constituent hormones. It is also pos-
sible that case patients and control subjects differentially reported 
their history of hormone use, but recall bias would generate a spu-
riously elevated OR associated with the exposure, whereas we 
observed an inverse association. 
 Fourth, we studied prevalent cases; on average, 5.6 years had 
elapsed between the diagnosis of breast cancer and the completion 
of the questionnaire. If previous HT use was associated with a 
decreased survival of breast cancer following a diagnosis of breast 
cancer, then we may see few HT users among long- time breast 
cancer survivors, resulting in a spurious negative association. 
 In conclusion, these data are reassuring in suggesting that HT 
is probably not contraindicated in women with a  BRCA1 mutation. 
Although the data cannot yet be considered defi nitive, we observed 
a statistically signifi cant reduction in the risk of breast cancer fol-
lowing HT use, in both the unadjusted and adjusted analyses. It is 
important that these fi ndings be replicated. The observed associa-
tions were not different for women who used estrogen alone or 
estrogen plus progesterone. There was little difference in the 
observed ORs associated with less than 3 years and 3 or more years 
of exposure, and therefore it is not possible for us to recommend 
an optimum duration of use. We did not include patients with 
 BRCA2 mutations in this study because the sample size was small. 
It is important that these data be confi rmed in other populations, 
including in women with  BRCA2 mutations. It is also important 
to evaluate the other risks and benefi ts associated with HT use in 
women at high risk for breast cancer. 
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